Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.62 |
| ▸ | CCND1 | P24385 | 18/20 | 0.62 |
| ▸ | CCND3 | P30281 | 14/20 | 0.62 |
| ▸ | CCND2 | P30279 | 10/20 | 0.62 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.61 |
| ▸ | CDK2 | P24941 | 5/20 | 0.61 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.61 |
| ▸ | CDK9 | P50750 | 4/20 | 0.61 |
| ▸ | CDK1 | P06493 | 2/20 | 0.61 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.61 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.56 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.56 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.56 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.56 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.56 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.56 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19294159 | 0.88 | CDK4 (0.64) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL28404189 | 0.87 | CDK4 (0.63) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL18788069 | 0.86 | CDK4 (0.62) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL29671046 | 0.86 | CDK4 (0.62) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL23913121 | 0.85 | CDK4 (0.61) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL18806093 | 0.84 | CDK4 (0.71) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL19021358 | 0.84 | CDK4 (0.60) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL17485622 | 0.83 | CDK4 (0.59) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL19021561 | 0.83 | CDK4 (0.66) | CDK4CCND1CCND3CCND2CDK6 | |
| SCHEMBL17485597 | 0.83 | CDK4 (0.48) | CDK4CCND1CCND3CCND2CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022091001-A1 | PROCESS FOR PREPARATION OF PALBOCICLIB | PFIZER IRELAND PHARMACEUTICALS (IE) | 2022-05-05 | — | — | WO | disclosed |
| US-11225492-B2 | Heterocycles useful as anti-cancer agents | HANGZHOU INNOGATE PHARMA CO., LTD. (CN) | 2022-01-18 | — | — | US | disclosed |
| EP-3386981-B1 | HETEROCYCLES USEFUL AS ANTI-CANCER AGENTS | HANGZHOU INNOGATE PHARMA CO LTD (CN) | 2021-10-13 | — | — | EP | disclosed |
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| EP-3172214-B1 | 2-AMINO-PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONE DERIVATIVES AS CDK INHIBITORS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-05-13 | — | — | EP | disclosed |
| CN-105294736-B | CDK small molecule inhibitor compound and application thereof | 广东东阳光药业有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | GUANGZHOU BEBETTER MEDICINE TECHNOLOGY CO., LTD. (CN) | 2019-01-22 | — | — | US | disclosed |
| US-20180087079-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-9828373-B2 | 2-amino-pyrido[2,3-D]pyrimidin-7(8H)-one derivatives as CDK inhibitors and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2017-11-28 | — | — | US | disclosed |
| US-20150353542-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | AMGEN INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-7456168-B2 | 2-(pyridin-2-ylamino)-pyrido[2,3, d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY | 2007-08-02 | — | — | US | disclosed |
| US-7208489-B2 | Inhibitors of cyclin-dependent kinases 4 (cdk4); treating proliferative disorders such as cancer; salt of 6-Acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one for example | WARNER-LAMBERT COMPANY (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1470124-B1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | WARNER LAMBERT CO (US) | 2005-12-28 | — | — | EP | disclosed |
| US-6936612-B2 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | WARNER-LAMBERT COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | WARNER-LAMBERT COMPANY | 2005-06-23 | — | — | US | disclosed |
| EP-1470124-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO 2,3-d]PYRIMIDIN-7-ONES | Warner-Lambert Company LLC (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | BARVIAN MARK (US) | 2003-08-07 | — | — | US | disclosed |
| WO-2003062236-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d]PYRIMIDIN-7-ONES | WARNER-LAMBERT COMPANY LLC (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225492-B2 | Heterocycles useful as anti-cancer agents | TP53, VHL, ABCG2 | CDK4 9/4885CCND1 42/4885CCND3 139/4885 |
| US-20030149001-A1 | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones | CDK4, CDK2, CDK1 | CDK4 1/4885CCND1 27/4885CCND3 44/4885 |
| US-20070179118-A1 | 2-(PYRIDIN-2-YLAMINO)-PYRIDO [2,3 D]PYRIMIDIN-7-ONES | CDK4, CDK2, CDKL4 | CDK4 1/4885CCND1 35/4885CCND3 46/4885 |
| US-20050137214-A1 | 2-(Pyridin-2-ylamino)-pyrido [2,3-D]pyrimidin-7-ones | CDK4, CDK2, CDK3 | CDK4 1/4885CCND1 34/4885CCND3 46/4885 |
| US-20180087079-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | CDKN1A, CDC25C, CDC25B | CDK4 18/4885CCND1 52/4885CCND3 58/4885 |
| US-10183941-B2 | Pyrimidine or pyridopyridone compound and application thereof | CDK6, CDK4, CDK2 | CDK4 2/4885CCND1 23/4885CCND3 45/4885 |
| US-20150353542-A1 | METHODS OF USING CELL-CYCLE INHIBITORS TO MODULATE ONE OR MORE PROPERTIES OF A CELL CULTURE | CDKN1A, CDC25C, CDC25B | CDK4 18/4885CCND1 52/4885CCND3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.